breast cancer. Malignant neoplasm of breast
Conditions
Interventions
In the intervention group after a course of chemotherapy (second or more) on a daily basis Hesa-a orally one tablet (50 mg) will start for three months
Intervention 1: The control group received placebo capsules (identical in shape Hesa-a capsules) One capsule (50 mg) daily through orally for three months. Intervention 2: In the intervention group a
Placebo
Treatment - Drugs
The control group received placebo capsules (identical in shape Hesa-a capsules) One capsule (50 mg) daily through orally for three months
Sponsors
Bushehr University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: age above 18 years and below 60 years, diagnosis of breast cancer oncologist and pathologist doctor (stage 3 and 4); history of at least one course of chemotherapy, no history of drug allergy Hsa-A Exclusion criteria from the study include: Forgot pills Hesa - A for five consecutive times or more, the use of drugs or other treatment methods to reduce the effects of other common medications prescribed by your doctor; the risk of problems and severe gastrointestinal side effects during the study, and eventually the desire to continue to participate in the study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of Life. Timepoint: Before the study, 45 days and 90 days after treatment. Method of measurement: questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of Life. Timepoint: Before the study, 45 days and 90 days after treatment. Method of measurement: questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDR. Shahnaz Pouladi
Bushehr University of Medical Sciences
Outcome results
None listed